logo

Eli Lilly And Co. (LLY)



Trade LLY now with
  Date
  Headline
9/14/2017 9:02:38 AM Lilly Says Baricitinib Meets Primary Endpoint In Phase 2 Study Of Patients With Moderate-to-Severe Atopic Dermatitis
9/12/2017 7:05:08 AM Lily Says Jardiance Tablets Reduced Risk Of Cardiovascular Death In People With Type 2 Diabetes
9/11/2017 9:03:40 AM Eli Lilly To Present New Data For Olumiant (baricitinib) And Taltz (ixekizumab) At EADV
9/8/2017 6:47:06 AM Eli Lilly Says Galcanezumab Shows Positive Long-Term Safety Results For Up To 12 Months In Patients With Migraine
9/7/2017 9:16:32 AM Eli Lilly To Streamline Business; To Impact Approximately 3,500 Positions
9/6/2017 6:46:01 AM Lilly To Present New Data For Galcanezumab And Lasmiditan At The 18th Congress Of The IHC
8/30/2017 6:45:43 AM Lilly To File Baricitinib Resubmission To U.S. FDA Before End Of Jan. 2018
8/29/2017 6:49:38 AM Eli Lilly And Co Says New Phase 3 Data For Abemaciclib And Ramucirumab Presented At ESMO 2017 Congress
8/21/2017 7:32:04 AM Invacare Corp Appoints Barbara Bodem To Board
8/4/2017 6:46:41 AM Lilly Announces Positive Results For Second Phase 3 Study Of Lasmiditan For Acute Treatment Of Migraine
7/26/2017 6:25:43 AM Jefferies Is Raising Eli Lilly And Co. (LLY) 2019 Rev. Estimate To 23.6 Billion From 23.4 Billion